Prevalence of diabetes and impaired glucose metabolism in younger 'at risk' UK adults: insights from the STAND programme of research by E.G. Wilmot (7243328) et al.
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
1 
 
Prevalence of diabetes and impaired glucose metabolism in younger ‘at 
risk’ UK adults: insights from the STAND programme of research 
 
EG Wilmot1,2, CL Edwardson2,3, SJH Biddle3,6, T Gorely4, J Henson1,2,6, K 
Khunti 2,5,6, MA Nimmo3,6, T Yates2,5,6, MJ Davies2,5,6 
 
1. Department of Cardiovascular Sciences, University of Leicester, University 
Hospitals of Leicester NHS Trust, Leicester General Hospital, Leicester, UK 
2. Leicester Diabetes Centre, University Hospitals of Leicester, UK 
 
3. School of Sport, Exercise and Health Sciences, Loughborough University, 
Loughborough, UK 
 
4. School of Sport, Stirling University, Stirling, UK  
5. Diabetes Research Unit, College of Medicine, Biological Sciences and 
Psychology, University of Leicester, UK 
6. NIHR Leicester-Loughborough Diet, Lifestyle and Physical Activity 
Biomedical Research Unit 
 
 
Corresponding Author and guarantor: 
 
Dr Emma Wilmot 
Leicester Diabetes Centre, Leicester General Hospital, Gwendolen Road 
Leicester, UK LE5 4PW 
Emma.Wilmot@uhl-tr.nhs.uk  
 
 
Funding: The STAND study is a MRC (NPRI) funded study (Project #91409). 
 
Conflicts of interest: The authors have no conflicts of interest to disclose. 
 
Novelty statements: 
 
• NICE guidance (2012) recommends screening younger high risk 
individuals (aged 25-39 years) for diabetes. 
• There is a lack of data on the prevalence of screen detected diabetes 
and impaired glucose metabolism in younger high risk UK adults. 
• A cohort of younger high risk UK adults underwent an oral glucose 
tolerance test and HbA1c. 4.7% were diagnosed with Type 2 DM; 
18.1% had impaired glucose metabolism. 
• These findings lend support to the recent NICE recommendations but 
will require confirmation in larger studies. 
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Abstract 
Aims: Rising rates of obesity have led to an increasing prevalence of Type 2 
diabetes mellitus (Type 2 DM) in young people. Uncertainty exists over the 
utility of screening younger adults for Type 2 DM as existing datasets have 
focused on mature (>40 years) cohorts. The aim of this study was to 
determine the prevalence of impaired glucose metabolism in higher risk 
younger adults. 
Methods: Overweight (with an additional risk factor) or obese adults (18-40 
years) were recruited for the Sedentary Time And Diabetes (STAND) 
randomised controlled trial. Measures included an oral glucose tolerance test 
(OGTT), HbA1c, biochemical and anthropometric data. 
Results: 193 individuals (68% female; median age 33.8 years; median BMI 
33.9 kg/m2) were recruited. 43% had a first degree family history of Type 2 
DM. Previously undiagnosed Type 2 DM was present in 4.7% (n=9). 18.1% 
(n=35) had impaired glucose metabolism: 4.7% (n=9) HbA1c ≥48mmol/mol 
(6.5%)); 9.3% (n=18) HbA1c 42-46mmol/mol (6.0-6.4%); 3.1% (n=6) Type 2 
DM on OGTT; 6.2% (n=12) isolated impaired glucose tolerance (IGT); 2.1% 
(n=4) isolated impaired fasting glucose (IFG); 1% (n=2) both IFG and IGT. 
58.5% (n=113) had dyslipidaemia, 28.0% (n=54) had hypertension, 31.1% 
(n=60) were vitamin D deficient and 7.3% (n=14) had abnormal liver function.  
Conclusions: This study identified a high prevalence of Type 2 DM and 
impaired glucose regulation in overweight and obese younger adults. These 
findings require confirmation in a larger, representative, population. 
 
Trial registration number: Current controlled trials ISRCTN08434554, MRC 
project 91409. 
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BACKGROUND 
The appeal and availability of sedentary pursuits and energy dense foods, 
alongside lower levels of occupational and other physical activities, has 
culminated in a worldwide obesity epidemic across all age ranges. This 
change has driven a dramatic shift in the traditional profile of chronic disease, 
and we now increasingly witness the development of Type 2 DM in young 
people [1]. The diagnosis of Type 2 DM at a young age has profound 
implications for both the individual and society. It is asymptomatic in the initial 
stages resulting in many developing irreversible complications, often before 
therapy has even begun. At diagnosis, approximately half of younger adults 
with Type 2 DM have hyperlipidaemia and/or hypertension and one in five has 
microalbuminurea [2-4]. This accelerated development of micro and macro-
vascular complications has serious repercussions. For instance, those 
diagnosed <45 years of age have a 14-fold increase in the risk of myocardial 
infarction compared to those without diabetes; and a 4-fold increase in risk 
compared to age matched controls who had Type 2 DM diagnosed >45 years 
[5]. In addition, early onset Type 2 DM is associated with co-morbidities such 
as fatty liver disease and obesity, independent risk factors for mortality [6, 7]. 
Type 2 DM in the young is a relatively recent phenomenon with limited long 
term follow up data but it is likely that it will culminate in excess morbidity and 
mortality.  
The early detection and management of Type 2 DM has the potential to 
reduce the impact of the disease. There is a legacy effect associated with 
early glycaemic control and even a modest delay in the diagnosis can have 
negative long term implications [8]. Identifying people at high risk of Type 2 
DM presents an opportunity to intervene and prevent the development of 
Type 2 DM. There is now a wealth of evidence from studies of older adults 
which illustrate that progression to Type 2 DM can be prevented or delayed 
with lifestyle changes which include increased physical activity and dietary 
modification [9, 10].  
The importance of the early detection of Type 2 DM in younger people has 
been acknowledged in the recent publication by the National Institute of 
Clinical Excellence (NICE) guidance which recommends screening high risk 
individuals aged 25-39 years of age [11]. Here, high risk includes black and 
minority ethnic groups (BME) and people with conditions that increase the risk 
of Type 2 DM. However, previous diabetes screening studies have 
predominantly focused on older adults, overlooking the potential disease 
burden in those younger than 40 years and the evidence base for this 
recommendation is currently lacking. We therefore investigated the 
prevalence of impaired glucose metabolism (IGM), Type 2 DM and 
cardiovascular risk factors in a multi-ethnic cohort of younger UK adults who 
were obese or overweight with at least one additional risk factor for the 
development of Type 2 DM. 
 
METHODS 
 
Study population and recruitment 
In 2011, 193 young adults aged 18-40 years were recruited from across 
Leicestershire and Northamptonshire, UK as part of Project STAND, a 2-arm 
parallel group randomised controlled trial. The methodology for this trial has 
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been described in detail elsewhere [12]. The study was granted ethical 
approval by the local Research Ethics Committee. Informed verbal and written 
consent was obtained from all participants. Inclusion criteria were age 18-40 
years with a BMI in the obese (≥30kg/m2 ; ≥27.5kg/m2 for South Asians) or 
overweight range (≥25kg/m2; ≥23kg/m2 for South Asians) plus an additional 
risk factor for Type 2 DM (family history of diabetes or cardiovascular disease 
in a first degree relative; previous gestational diabetes; polycystic ovarian 
syndrome). Exclusion criteria included significant illness, steroid use, pre-
existing diabetes (self reported or recorded on GP database), pregnancy or 
an inability to communicate in English. Recruitment was co-ordinated via the 
East Midlands and South Yorkshire Primary Care Research Network. An 
electronic general practice (GP) database search was conducted to identify 
participants who met the inclusion criteria. Invitations were sent by the GP to 
the participants who then replied directly to the study team.  
 
Study measures 
Nurse administered questionnaires were used to assess medical history, drug 
and family history, smoking status and ethnicity. Arterial blood pressure was 
measured in the sitting position (Omron, Healthcare, Henfield, UK); three 
measurements were obtained and the average of the last two measurements 
used. Hypertension was defined as a systolic blood pressure ≥140 or diastolic 
≥90 mmHg or treatment for hypertension [13]. Other measures included body 
weight and body fat percentage (Tanita BC 420SMA, Tanita, West Drayton, 
UK), waist circumference (midpoint between the lower costal margin and iliac 
crest), and height to the nearest 0.1 kg, 0.5% and 0.5 cm respectively.  
 
Glycaemia 
Participants were invited to attend a baseline measurement session after a 
12-hour fast and 24 hours of avoiding vigorous intensity exercise. Individuals 
underwent a standardized 75g OGTT and an HbA1c to measure glycaemia. 
HbA1c was interpreted according to the 2011 WHO criteria (HbA1c 
≥48mmol/mol (6.5%) diabetes; 42-46 mmol/mol (6.0-6.4%) “high risk”) [14, 
15]. The OGTT results were interpreted according to the 1999 WHO criteria 
and divided into diabetes, isolated impaired fasting glycaemia (IFG), isolated 
impaired glucose tolerance (IGT) or impaired glucose regulation (IGR) (both 
IFG and IGT) [16]. In this study, diabetes is defined by an OGTT and/or 
HbA1c result in the diabetes range. Impaired glucose metabolism (IGM) refers 
to any previously undiagnosed glucose abnormality including an 
HbA1c≥42mmol/l (6%) and/or OGTT defined IFG, IGT or Type 2 DM.  
 
Laboratory analysis 
Serum total cholesterol, HDL cholesterol, and triglycerides; liver function, urea 
and creatinine and 25-hydroxyvitamin D were measured. Low density 
lipoprotein cholesterol (LDL) was estimated using the Friedewald equation 
[17]. Dyslipidaemia was defined as lipid lowering treatment or triglycerides 
≥1.7 mmol/l or HDL <1.03 (males) and <1.29 mmol/l (females) [18]. Plasma 
glucose, lipids and liver function tests were all measured using standard 
enzymatic endpoint methods on an ADVIA Chemistry System (Bayer 
Healthcare, NY, USA). An abnormal ALT was defined as >53iU/L. HbA1c was 
measured by ion exchange liquid chromatography (G7; Tosoh, Tokyo, Japan). 
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25-Hydroxyvitamin D (25(OH)D) was quantified using liquid chromatography 
mass spectrometry (6410 Triple Quad, Agilent Technologies UK Ltd, 
Wokingham, UK). 
 
Statistical methods 
Normality was assessed using the Kolmogorov-Smirnov test, histograms and 
normal Q-Q plot. Continuous data were expressed as mean (standard 
deviation (SD)) if they were normally distributed. Non-parametric continuous 
variables were expressed as median (25% and 75% interquartile range (IQR)). 
Categorical data were expressed as a percentage. Chi square was used to 
compare categorical variables between two groups. Statistical tests were 
performed using SPSS 18.0 software (Statistical Package for the Social 
Sciences, Chicago, IL). p<0.05 was considered statistically significant. 
 
 
RESULTS 
193 participants who completed the STAND study baseline visit were 
included. 68% (n=131) were female. 21% (n=40) were of BME origin (Asian 
n=23; Black n=10; mixed ethnic origin n=7). Median (+/-interquartile range) 
age and BMI were 33.8 (29.3-37.9) years and 33.9 (31.2-37.6) kg/m2 
respectively. 43% had a first degree family history of Type 2 DM. Baseline 
anthropometric and laboratory data are described in Table 1. 
 
Prevalence of impaired glucose metabolism 
Diabetes was present in 4.7% (n=9) of the study population. IGM was present 
in 18.1% (n=35). Of those with IGM, 4.7% (n=9) had an HbA1c ≥48mmol/mol 
(6.5%)); 9.3% (n=18) HbA1c 42-46mmol/mol (6.0-6.4%); 3.1% (n=6) Type 2 
DM on OGTT; 6.2% (n=12) isolated IGT; 2.1% (n=4) isolated IFG; 1% (n=2) 
both IFG and IGT. 32.5% (n=13) of the BME population had IGM compared to 
14.5% (n=22) of the White Caucasian population (p=0.01). 15.3% (n=20) of 
females had IGM compared to 24.2% (n=15) males (p=0.13). All participants 
aged <25 years (n=22) had normal glucose status.  
 
 
Cardiometabolic risk 
58.5% (n=113) had dyslipidaemia and 28.0% (n=54) had hypertension.  0.5% 
(n=1) and 4.7% (n=9) were prescribed lipid lowering and anti-hypertensive 
therapy respectively. 7.3% (n=14) had an elevated alanine transferase, a 
marker of possible fatty liver disease. 31.1% (n=60) were vitamin D deficient 
(<30nmol/l). 
 
CONCLUSIONS 
Screening young overweight and obese adults for Type 2 DM successfully 
identified diabetes (4.7%) and impaired glucose metabolism (18.1%). The 
diabetes yield in this cohort was similar to other larger screening studies in 
older UK populations and adds further support to the recent national 
recommendation to screen those aged 25-39 years for diabetes [11].  
The ADDITION-Leicester population based diabetes screening study, with a 
mean age 57 years, identified 3.3% of the population with undiagnosed Type 
2 DM [19]. These data were based on OGTT results and are comparable with 
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the OGTT diabetes yield (3.1%) in the younger high risk STAND cohort. 
Similar figures have been reported in other UK studies in overweight and 
obese populations >40 years, with reported yields between 1.4% and 5.4% 
[20, 21]. However, it is important to highlight that the STAND cohort were a 
high risk group and not representative of the general Leicester population. In 
Leicester 23% of the population are obese and 36% of BME origin compared 
to 89% and 21% of the STAND study population respectively [22,23]. The 
BME populations were underrepresented in this study, a group which typically 
has more than double the prevalence of screen detected diabetes [19]. These 
factors limit the generalisability of our findings.  Nonetheless, the yield 
obtained highlights that undetected Type 2 DM is prevalent in high risk young 
cohorts and is worth pursuing. Furthermore, NICE recommend targeted 
screening towards minority ethnic groups, a recommendation supported by 
our finding of significantly more IGM in the BME group. However, the 
prevalence of IGM (14.5%) and Type 2 DM (2%) in the White Caucasian 
population was still considerable. The increasing prevalence of abnormal 
glucose metabolism in younger White Caucasian adults is recognised and 
requires further exploration in larger studies [24]. 
The prevalence of IGM in this younger population has implications for clinical 
practice. Type 2 DM in younger people represents an aggressive phenotype 
with multiple co-morbidities (hyperlipidaemia, non alcoholic fatty liver disease, 
morbid obesity) and the rapid development of complications such as 
nephropathy and hypertension, often more quickly than people with Type 1 
DM and despite relatively tight glycaemic control [2]. Early detection of Type 2 
DM in this group is paramount in order to prevent the development of 
irreversible complications during their working lives. This is particularly 
important in young women of child bearing age. If a woman with undiagnosed 
Type 2 DM becomes pregnant, there is substantial risk to the unborn foetus, 
particularly during organogenesis in the first trimester when congenital defects 
occur in the presence of uncontrolled hyperglycaemia [25]. Such risks can be 
minimised by tight glycaemic control and high dose folic acid in early 
pregnancy [25].  In view of the high rates of IGM in our young cohort, it would 
seem sensible to consider diabetes screening in obese women and 
overweight women with a family history of diabetes or cardiovascular disease. 
The main strengths of this study are the unique insights into the prevalence of 
dysglycaemia and cardiovascular risk factors in a younger high risk UK 
population. However, interpretation of the data requires some caution given 
the sample size, small in comparison to large diabetes screening studies. 
Also, these participants were motivated subjects who volunteered for inclusion 
in a randomised controlled behavioural intervention trial on the basis of being 
‘at risk’, and this may limit how generalisable the findings are. However, few 
data are available on the prevalence of impaired glucose metabolism in this 
group so the findings of this study fill a gap in current knowledge.  
In conclusion, screening for Type 2 DM in a high risk multi-ethnic population 
of younger adults successfully identifies Type 2 DM and IGM. The findings will 
need confirmation in larger populations. 
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Table 1. Anthropometric and laboratory outcomes 
 
Descriptive (n=187-193) n= Median/% (IQR) 95% CI 
Age (years) 193 33.8 (29.3-37.9) 32.1-33.7 
Gender (% female) 193 67.9  
Ethnicity (% BME) 193 20.7  
Systolic BP (mmHg) 193 119 (112-129) 119.1-123.2 
Diastolic BP (mmHg) 193 83 (78-89) 82.7-85.5 
BMI (kg/m2) 193 33.9 (31.2-37.6) 33.9-35.3 
Obese (%) 193 88.6  
Waist (cm) 193 101 (94-111) 102-105 
Waist Hip Ratio 193 0.88 (0.81-0.95) 0.87-0.90 
Body fat (%) 193 41.9 (35.2-46.2) 39.6-41.6 
Fat free mass (%) 193 53.9 (49.4-66.3) 55.7-59.4 
Cholesterol (mmol/l) 192 4.8 (4.2-4.8) 4.8-5.1 
LDL (mmol/l) 188 3.0 (2.4-3.4) 2.9-3.1 
HDL(mmol/l) 191 1.2 (1.0-1.4) 1.2-1.3 
Trig(mmol/l) 192 1.3 (0.9-1.9) 1.4-1.8 
HbA1c (mmol/mol) 191 46 (36-40) 38-39 
HbA1c (%) 191 5.6 (5.4-5.8) 5.6-5.7 
Fasting glucose (mmol/l) 192 4.8 (4.5-5.1) 4.8-5.2 
2 hour glucose (mmol/l) 192 5.2 (4.3-6.4) 5.3-6.1 
ALT (iu/l) 192 23 (17.34) 26.0-31.2 
AST (iu/l) 187 22 (18-29) 23.2-25.7 
Vitamin D <30nmol/l (%) 190 31.1  
Results presented as median (interquartile range (IQR)) or percentage (%). BME = black or 
minority ethnic group. 
 
 
 
 
 
 
 
 
 
